Angiogenesis: Future of pharmacological modulation

Indian Journal of Pharmacology

Volumn 42, Issue 1, 2010, Pages 2-8

  Bisht, Manisha ^a   Dhasmana, D C ^a   Bist, S S ^a  

^a HIMALAYAN INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Angiogenesis; Antiangiogenic drugs; Vascular endothelial growth factor

Indexed keywords

ALITRETINOIN; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOPOIETIN; ANGIOSTATIN; BASIC FIBROBLAST GROWTH FACTOR; BECAPLERMIN; BEVACIZUMAB; BORTEZOMIB; CELL ADHESION MOLECULE; CETUXIMAB; CHEMOKINE; ERLOTINIB; EVEROLIMUS; IMIQUIMOD; LENALIDOMIDE; MATRIX METALLOPROTEINASE; PANITUMUMAB; PEGAPTANIB; PROTEIN P53; RANIBIZUMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; THROMBOSPONDIN 1; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADVANCED CANCER; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANGIOGENESIS; ANGIOMA; ANTIANGIOGENIC ACTIVITY; ATHEROSCLEROSIS; BLOOD VESSEL; BRAIN ISCHEMIA; BREAST CANCER; CANCER GRAFT; CELL ACTIVATION; CELL COUNT; CELL DIFFERENTIATION; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CHEMOTAXIS; CHICK; CHORIOALLANTOIS; CHRONIC WOUND; COLORECTAL CANCER; CORNEA; DIABETIC FOOT; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DOWN REGULATION; DRUG INDICATION; EMPHYSEMA; ENDOMETRIOSIS; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GASTRODUODENAL ULCER; HEAD AND NECK CANCER; HEART MUSCLE ISCHEMIA; HELICOBACTER PYLORI; HEMANGIOENDOTHELIOMA; HEMANGIOMA; HUMAN; HYPOXIA; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; ISCHEMIA; KAPOSI SARCOMA; KIDNEY CARCINOMA; KIDNEY DISEASE; LIVER CELL CARCINOMA; LUNG FIBROSIS; LUNG SMALL CELL CANCER; MESENCHYME CELL; MICROVASCULATURE; MOTONEURON; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEOVASCULARIZATION (PATHOLOGY); NERVE CELL DEGENERATION; NONHUMAN; OSTEOLYSIS; PALLOR; PANCREAS CANCER; PATHOGENESIS; PERICYTE; PERIPHERAL ISCHEMIA; PLASTIC SURGERY; PREECLAMPSIA; PROTEIN DEGRADATION; PSORIASIS; PURPURA; RABBIT; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; STOMACH ULCER; STROKE; SURVIVAL; TELANGIECTASIA; TISSUE GRAFT; VASCULARIZATION; WOUND HEALING;

EID: 77951672380     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.62395     Document Type: Review

References (43)

1. Patan S. Vasculogenesis and angiogenesis as mechanisms of vascular network formation, growth and remodeling. J Neuro Oncol 2000;50:1-15.
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
3. The angiogenesis foundation. Understanding angiogenesis (document on the internet) Cambridge: The organization; 1994. [updated on 2009 Jul 10] [cited on 2009 Jul 12]. Available from http://www.angio.org/ua.php.
4. Papetti M, Herman IM. Mechanisms of normal and tumour-derived angiogenesis. Am J Physiol Cell Physiol 2002;282:C947-70.
5. Ausprunk DH, Folkman J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res 1977;14:53-65.
6. Bischoff J. Cell adhesion and angiogenesis. J Clin Invest 1997;100:S37-9
7. Liekens S, Clereq ED, Neyts J. Angiogenesis: Regulators and clinical applications Biochem Pharmacol 2001;61:253-70.
8. Dorrell M, Jarvinen HU, Aguilar E, Friedlander M. Ocular neovascularisation Basic mechanism and therapeutic advances. Surv Ophthalmol 2007;52:S3-19
9. Domenico R, Maria TC, Gastone G. Nonclassic endogenous novel regulators of angiogenesis. Pharmacol Rev 2007;59:185-205
10. Veikkola T, Alitalo K. VEGFs, receptors and angiogenesis. Semin Cancer Biol 1999;9:211-20.
11. Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugge JS, Sukhatme VP Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 1995;375:577-81.
12. Presta M, Moscatelli D, Joseph-Silverstein J, Riflkin DB. Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molecule that stimulates capillary endothelial cell plasminogen activator production, DNA synthesis, and migration. Mol Cell Biol 1986;6:4060-6.
13. Nguyen M. Angiogenic factors as tumor markers. Invest New Drugs 1997;15:29-37
14. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN et al. Requisite role of angiopoietin-1: A ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996;87:1171-80.
15. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277:55-60
16. Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis Dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 1999;18:5356-62
17. Montesano R, Pepper MS, Vassalli JD, Orci L. Modulation of angiogenesis in vitro. EXS 1992;61:129-36.
18. Ribatti D, Vacca A. Models for studying angiogenesis in vivo. Int J Biol Markers 1999;14:207-13.
19. Jenkinson L, Bardhan KD, Atherton J, Kalia N. Helicobacter pylori prevents proliferative stage of angiogenesis in vitro: Role of cytokines. Dig Dis Sci 2002;47:1857-62.
20. Maynard SE, Min J, Merchan J, Lim KH, Li J, Mondal S, et al. Excess Placental sFlt-1 may contribute to endothelial dysfunction, hypertension and proteinuria in preeclampsia. J Clin Invest 2004;111:649-58.
21. Kang DH, Anderson S, Kim YG, Mazzalli M, Suga S, Jefferson JA, et al. Impaired angiogenesis in the aging kidney: VEGF and thrombospondin-1 in renal disease Am J Kidney Dis 2001;37:601-11.
22. Martinez P, Esbrit P, Rodrigo A, Alvarez-Arroyo MV, Martínez ME. Age-related changes in parathyroid hormone-related protein and VEGF in human osteoblastic cells. Osteoporos Int 2002;13:874-81.
23. Chang E, Yang J, Nagavarapu U, Herron GS. Aging and survival of cutaneous microvasculature. J Invest Dermatol 2002;118:752-8
24. Koyama S, Sato E, Haniuda M, Numanami H, Nagai S, Izumi T. Decreased level of VEGF in bronchoalveolar lavage fluid of normal smokers and patients with pulmonary fibrosis. Am J Respir Crit Care Med 2002;166:382-5
25. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman S, Hirth PK et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema J Clin Invest 2000;106:1311-9.
26. Krupinski J, Kaluza J, Kumar P, Kumar S, Wang JM. Role of angiogenesis in patients with cerebral ischemic stroke. Stroke 1994;25:1794-8
27. Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, Brusselmans K, et al. Deletion of the hypoxia-response element in the VEGF promoter causes motor neuron degeneration. Nat Genet 2001;28:131-8.
28. De La Torre JC. Alzheimer's disease: How does it start? J Alzheimers Dis 2002;4:497-512.
29. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-60
30. Rupnick MA, Panigrahy D, Zhang CY, Dallabrida SM, Lowell BB, Langer R, et al. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci USA 2002;99:10730-5.
31. Harada K, Lu S, Chisholm DM, Syrjänen S, Schor AM. Angiogenesis and vasodilation in skin warts: Association with HPV infection. Anticancer Res 2000;20:4519-23.
32. Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002;106:2781-6.
33. Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest 1999;103:1231-6
34. Li J, Post M, Volk R, Gao Y, Li M, Metais C, et al. PR39, a peptide regulator of angiogenesis. Nat Med 2000;6:49-55.
35. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, et al. Role of HIF-1a in hypoxia-mediated apoptosis, cell proliferation and tumor angiogenesis. Nature 1998;394:485-90.
36. Jain RK, Munn LL. Leaky vessels? Call Ang1!. Nat Med 2000;6:131-2.
37. Carmeliet P, Ng YS, Nuyens D, Theilmeier G, Brusselmans K, Cornelissen I et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the VEGF isoforms VEGF164 and VEGF188. Nat Med 1999;5:495-502
38. Streit M, Velasco P, Brown LF, Skobe M, Richard L, Riccardi L, et al. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol 1999;155:441-52.
39. Cao Y. Therapeutic potentials of angiostatin in the treatment of cancer Haematologica 1999;84:643-50.
40. Wen W, Moses MA, Wiederschain D, Arbiser JL, Folkman J. The generation of endostatin is mediated by elastase. Cancer Res 1999;59:6052-6
41. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999;285:1926-8
42. Turk BE, Griffith EC, Wolf S, Biemann K, Chang YH, Liu JO. Selective inhibition of amino-terminal methionine processing by TNP-470 and ovalicin in endothelial cells. Chem Biol 1999;6:823-33.
43. 3 integrin receptor, in patients with advanced solid tumors Invest New Drugs 2008;26:35-43